More on SUPN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $46.20 |
|
|||
| Open | $46.56 | ||||
| 52 Wk High | $26.84 | ||||
| 52 Wk Low | $9.51 | ||||
| Day High | $48.08 | ||||
| Day Low | $45.84 | ||||
| P/E | N/A | ||||
| EPS | $-2.62 | ||||
| Volume | 523,012 | ||||
- Form 8-K SUPERNUS PHARMACEUTICALS For: Jul 22
- Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
- Supernus Pharma (SUPN) call put ratio 1 call to 4 puts
- Supernus marks five years of Qelbree ADHD drug with 3M prescriptions
- Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
- Form S-8 SUPERNUS PHARMACEUTICALS
- Form 8-K SUPERNUS PHARMACEUTICALS For: Jun 18
- Supernus names MERGE as agency of record for its CNS portfolio
- Supernus Expands Partnership With MERGE as AI-Powered Agency of Record
- Supernus Pharmaceuticals to Participate in June Investor Conferences
Entities mentioned with SUPN
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Jefferies & Co | View Related Stories »
- PDUFA | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
